BioSyent to Showcase Growth Story at Premier Investor Conference

MISSISSAUGA, Ontario – April 15, 2026 – As investors gather for Canada's premier healthcare investment event, the Bloom Burton & Co. Healthcare Investor Conference, one company arrives with a compelling narrative of sustained profitability and aggressive strategic expansion. BioSyent Inc. (TSX Venture: RX), a specialty healthcare products company, is set to present its case to a discerning audience, and its story is one that stands out in a cautious market.

President and CEO René Goehrum will take the stage in Toronto on April 21st to provide an overview of the company’s business activities. While the presentation is a standard feature of the conference, the context surrounding BioSyent's appearance is anything but. Fresh off a transformative acquisition and boasting a financial track record of remarkable consistency, the company is poised to detail a growth model that appears tailor-made for the current investment climate, which favors proven commercial success over speculative ventures.

A Record of Consistent Profitability

In an industry often characterized by high-risk, high-reward ventures, BioSyent has carved out a niche as a beacon of stability and reliable growth. The company's upcoming presentation is underpinned by an impressive financial foundation: 62 consecutive profitable quarters. This streak of uninterrupted profitability, stretching back to mid-2010, speaks volumes about its resilient business model and disciplined operational management.

Full-year results for 2025, reported on March 19, 2026, painted a picture of robust health. The company announced total sales of CAD $43.05 million, a 23% increase over the prior year. This top-line growth translated directly to the bottom line, with net income after taxes rising 24% to CAD $9.01 million. Fully diluted earnings per share (EPS) saw a 27% jump to CAD $0.78, a metric sure to capture investor attention. Furthermore, the company maintains a strong balance sheet with low leverage, a factor that provides both stability and the flexibility to pursue strategic opportunities.

This performance has not gone unnoticed by the market. BioSyent's stock has outperformed both the Canadian Pharmaceuticals industry and the broader Canadian market over the past year. In a show of confidence, the company also rewarded its shareholders by increasing its quarterly dividend by 10% earlier this year, signaling management's positive outlook on future cash flows.

Strategic Acquisitions Fueling Diversification

BioSyent's success is not accidental; it is the result of a deliberate strategy focused on what market analysts call "derisked innovation." Rather than engaging in costly and uncertain early-stage drug development, the company specializes in acquiring or in-licensing innovative products that are already proven safe and effective. This approach minimizes risk while allowing the company to leverage its marketing and distribution expertise to drive growth.

The cornerstone of its portfolio has long been the FeraMAX® Pd platform. For 11 consecutive years, FeraMAX® has been the number-one recommended over-the-counter oral iron supplement by Canadian pharmacists, providing a steady and significant revenue stream. The company has skillfully expanded this franchise with new formulations like FeraMAX® Pd Maintenance 45, targeting different patient needs and solidifying its market dominance.

However, it is the company's recent strategic moves that will likely be the centerpiece of Mr. Goehrum's presentation. The 2024 acquisition of the worldwide rights to Tibella®/Tibelia®, a hormone replacement therapy, has been a game-changer for its international pharmaceutical segment, which saw sales grow by over 300% in 2025. This move demonstrated BioSyent's ability to identify and integrate assets with global potential.

More recently, the company made its most significant move to date with the March 2026 acquisition of Oral Science Inc. for $25.5 million. This transformative, "bolt-on" acquisition dramatically expands BioSyent's footprint in the burgeoning oral health market. Oral Science, a distributor of specialized dental hygiene products with over $30 million in trailing twelve-month revenue, gives BioSyent immediate scale and deep relationships with Canadian dental professionals. The combined pro-forma revenue of the two entities is projected to exceed $70 million, effectively diversifying BioSyent's business and creating a powerful new growth engine. This entry into the oral health space is particularly timely, as the newly implemented Canadian Dental Care Plan (CDCP) is expected to increase patient demand for preventive care services, creating a significant tailwind for the sector.

The Pitch to a Discerning Market

BioSyent's presentation at the Bloom Burton & Co. conference comes at an opportune moment. After a period of volatility, investors in the Canadian health tech and specialty pharma sectors have become more selective. The preference has shifted away from early-stage companies with long, uncertain paths to profitability and toward established players with strong commercial traction and clear return on investment. BioSyent's story of sustained profitability, shareholder returns, and strategic, accretive acquisitions aligns perfectly with this sentiment.

Leading the charge is CEO René Goehrum, whose nearly 27-year tenure at the helm provides a level of stability and long-term vision that is rare. As a significant shareholder himself, his interests are deeply aligned with those of other investors. His track record of steering the company through various market cycles while maintaining profitability and executing key acquisitions like Tibelia® and Oral Science lends significant credibility to the company's future plans.

For the Canadian, U.S., and international investors attending the conference, BioSyent represents a compelling case study in disciplined growth. The one-on-one meetings available with Mr. Goehrum will offer a chance for a deeper dive into this strategy, allowing potential investors to probe the synergies of the Oral Science acquisition and understand the company’s pipeline for future growth.

Navigating the Future with a Loaded Pipeline

While its current portfolio is robust, BioSyent is not resting on its laurels. The company's growth strategy remains forward-looking, with a continued focus on expanding its product offerings. A key topic for investors will be the status of a new endocrinology product, for which the company has secured an exclusive Canadian license from a European partner. This product, aimed at addressing an unmet medical need, is currently awaiting regulatory approval from Health Canada and represents the next potential catalyst for the Canadian pharma business.

This commitment to continuously expanding its pipeline through in-licensing and acquisitions is central to BioSyent's long-term vision. By identifying and securing innovative products in therapeutic areas like oncology supportive care (Gelclair®) and women's health (Inofolic®), the company mitigates reliance on any single product and builds a diversified portfolio capable of weathering market shifts and navigating regulatory challenges, such as potential changes to Canada's Patented Medicine Prices Review Board (PMPRB) guidelines.

As Mr. Goehrum prepares to address the investment community, his message will be clear: BioSyent is not just a company with a strong past, but one with a well-defined and executable plan for the future. It is a story of profitable growth, strategic diversification, and experienced leadership, making it a standout name to watch at this year's conference.